NCT04000737 2025-04-13
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Yiviva Inc.
Phase 2 Completed
Clinical Trials
5 trialsNCT01666756 2021-01-27
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00411762 2015-03-27
A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma
Yale University
Phase 1/2 Completed
NCT00076609 2007-03-28
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
PhytoCeutica
Phase 1/2 Completed
NCT00036517 2005-06-24
Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer
PhytoCeutica
Phase 1/2 Terminated